Ignite Creation Date:
2025-12-24 @ 7:51 PM
Ignite Modification Date:
2025-12-29 @ 2:50 AM
Study NCT ID:
NCT00085904
Status:
COMPLETED
Last Update Posted:
2008-10-13
First Post:
2004-06-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas
Sponsor:
GlaxoSmithKline
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2004-04
Start Date Type:
None
Primary Completion Date:
None
Primary Completion Date Type:
None
Completion Date:
None
Completion Date Type:
None
First Submit Date:
2004-06-16
First Submit QC Date:
None
Study First Post Date:
2004-06-18
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2008-10-09
Last Update Post Date:
2008-10-13
Last Update Post Date Type:
ESTIMATED